NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)Rizwan Romee, Jeffrey S. Miller, Bree Foley et al.|Blood|2013Cited by 537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Jeffrey S. Miller, Peter Westervelt et al.|Blood|2018Cited by 406
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Clinical Cancer Research|2018Cited by 195
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemiaDavid A. Rizzieri, Gautam Borthakur, Sarah Cooley et al.|Leukemia & lymphoma/Leukemia and lymphoma|2016Cited by 78
Supplementary Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Unknown|2023Cited by 0